Andarine (GTX-007)

Andarine (GTX-007) is an investigational selective androgen receptor modulator (SARM) and an active partial agonist for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy, using the non-steroidal androgen antagonist bicalutamide as a lead compound.Andarine (GTX-007) is an orally active partial agonist for androgen receptors. Andarine (GTX-007) is less potent in both anabolic and androgenic effects than other SARMs. In an animal model of benign prostatic hypertrophy, andarine was shown to reduce prostate weight with similar efficacy to finasteride, but without producing any reduction in muscle mass or anti-androgenic side effects. Clinical development of Andarine has been abandoned, given in humans it results in a series specific toxic metabolite. ^{[1][2][3][4][5]}

• [1] J Pharmacol Exp Ther 2003 March;304(3): 1334–1340
• [2] Mol Interv 2005 June;5(3): 173–188
• [3] Endocrinology 2004 December;145(12): 5420–5428
• [4] Pharm Res 2006 August;23(8): 1641–1658
• [5] DRUG METABOLISM AND DISPOSITION 2006;34:254–260